Jade Biosciences, Inc. Increase (Decrease) in Other Noncurrent Assets
Jade Biosciences, Inc. (JBIO) reported Increase (Decrease) in Other Noncurrent Assets of $38.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-10
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-06-30 was $148.00K.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-03-31 was -$60.00K.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2024-12-31 was $226.00K, a 465.00% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2024-09-30 was $1.72M, a 11373.33% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was $38.00K.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was -$563.00K, a 611.82% decline from fiscal 2023.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $110.00K, a 94.12% decline from fiscal 2022.
- Jade Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $1.87M, a 519.87% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 6 month as first filed | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $38.00K 10-K · filed 2026-03-06 | ||||
| 2025-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $88.00K 10-Q · filed 2026-08-10 | -$88.00K 10-Q · filed 2025-08-13 | $314.00K derived: sum of 3 quarters · filed 2026-08-10 | $2.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$60.00K 10-Q · filed 2026-05-07 | $166.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.89M derived: sum of 3 quarters · filed 2026-05-07 | -$621.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.95M derived: sum of 2 quarters · filed 2025-03-27 | -$561.00K derived: sum of 3 quarters · filed 2025-03-27 | -$563.00K 10-K · filed 2025-03-27 | |
| 2024-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$787.00K derived: sum of 2 quarters · filed 2024-11-12 | -$789.00K 10-Q · filed 2024-11-12 | -$749.00K derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-06-30 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$2.51M 10-Q · filed 2024-08-12 | -$2.47M derived: sum of 3 quarters · filed 2025-04-25 | -$2.46M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$2.00K 10-Q · filed 2025-04-25 | $38.00K derived: sum of 2 quarters · filed 2025-04-25 | $53.00K derived: sum of 3 quarters · filed 2025-04-25 | $19.00K derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $55.00K derived: sum of 2 quarters · filed 2025-03-27 | $21.00K derived: sum of 3 quarters · filed 2025-03-27 | $110.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$19.00K derived: sum of 2 quarters · filed 2024-11-12 | $70.00K 10-Q · filed 2024-11-12 | $1.53M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $55.00K 10-Q · filed 2024-08-12 | $1.52M derived: sum of 3 quarters · filed 2024-08-12 | $1.50M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $89.00K 10-Q · filed 2024-05-13 | $1.55M derived: sum of 2 quarters · filed 2024-05-13 | $1.53M derived: sum of 3 quarters · filed 2024-05-13 | $1.94M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.44M derived: sum of 2 quarters · filed 2024-03-25 | $1.85M derived: sum of 3 quarters · filed 2024-03-25 | $1.87M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $382.00K derived: sum of 2 quarters · filed 2023-11-13 | $407.00K 10-Q · filed 2023-11-13 | $431.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $403.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $428.00K 10-Q · filed 2023-08-14 | $452.00K derived: sum of 3 quarters · filed 2023-08-14 | $656.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $25.00K 10-Q · filed 2023-05-15 | $49.00K derived: sum of 2 quarters · filed 2023-05-15 | $253.00K derived: sum of 3 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $228.00K derived: sum of 2 quarters · filed 2023-03-29 | $302.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $278.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $74.00K 10-Q · filed 2022-08-15 | ||||
| 2020-06-30 | $2.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |